Introduction
============

According to the recent study, cardiovascular diseases (CVDs) are highly prevalent globally and produce immense health and economic burdens in the United States and the world ([@B117]). The pathophysiological and physiological changes accompanied with vascular aging lead to compromised cardiovascular functions and elevated risks of CVDs including atherosclerosis, hypertension, and diabetes in elder population ([@B21]). Peripheral arterial disease (PAD) and coronary heart disease including myocardial infarction (MI) account for most of all CVDs ([@B117]). Except for genetic defects, most CVDs can be attributed to unhealthy lifestyle factors such as high fat diet, high salt diet, and smoking ([@B117]).

With the advances in our understanding of the underlying mechanisms of CVDs, breakthrough has been achieved in diagnosis and intervention, such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and heart transplantation. However, to some degree, these approaches can only delay the heart failure ([@B110]). This burden of disease has driven the investigation of stem/progenitor cell-based therapy for the CVDs. Experimental studies suggested that administration of endogenous stem/progenitor cells may contribute to functional regeneration of infarcted myocardium and repair damaged/injured endothelial cells ([@B121]). Over the past decades, stem or progenitor cell-based therapy has emerged as a promising approach for the treatment of various CVDs, such as MI, heart failure, and PAD ([@B115]). The efficacy of various stem/progenitor cells including endothelial progenitor cells (EPCs) ([@B51]), hematopoietic stem cells (HSCs) ([@B77]), cardiac stem cells (CSCs) ([@B58]), and bone-marrow derived mononuclear cells (MNCs) ([@B116]) in treating CVDs has already been evaluated in clinical trials. The potential therapeutic applications of stem/progenitor cells, such as embryonic stem cells (ESCs) ([@B100]) and mesenchymal stem cells (MSCs) ([@B66]), have been investigated in experimental and preclinical studies. As endothelial dysfunction is one of the major problems for CVDs, there is an increasing interest and ongoing efforts to study EPCs and other stem/progenitor cell-derived endothelial cells as potential sources for cell therapy ([@B84]). Here we summarize the studies using endothelial stem/progenitor cells and their derivatives, or sometimes oversimplified as "EPCs," in the treatment of CVDs.

Cell Spectrum of Stem/Progenitor Cell Derived Endothelial Cells
===============================================================

MSCs
----

Mesenchymal stem cells were originally identified and characterized by [@B27] in the 1970s. MSCs have been found in multiple organs throughout the body including bone marrow (BM), umbilical cord, placenta, dental pulp, and adipose tissue and their characteristics have been reviewed recently ([@B43]). MSCs derived from BM, adipose tissue, and umbilical cord have been widely used in preclinical and clinical trials. It has been reported that adipose-derived stromal/stem cells (ASCs) possess strong angiogenic potential and paracrine activities ([@B10]). Early phase clinical trials have shown that ASC transplantation has improved rest pain, ulcer surface, walking distance, pain-free walking time, and transcutaneous oxygen pressure in PAD patients ([@B50]). MSCs possess several advantages as one of the promising candidates for stem/progenitor cell-based therapy: First, MSCs are easy to isolate and expand; Second, MSCs can secrete growth factors or directly differentiate into vascular cells or myocytes to contribute to arteriogenesis and angiogenesis ([@B114]); Third, MSCs hold an immunoregulatory capacity and immunosuppressive effect indicating their potential of autotransplantation ([@B17]). These advantages enable MSCs to improve the neovascularization and blood flow in PAD and MI related ischemic tissues ([@B38]; [@B29]). Though with limitations such as the low retention and survival of transplanted MSCs ([@B68]), the cell pretreatment and genetic engineering approaches will provide a promising future for MSC based therapy ([@B53]).

iPSCs
-----

Induced pluripotent stem cells (iPSCs), which exhibit pluripotent differentiation and self-renewal potential that are similar to that of ESCs, was originally reported by [@B108]. By introducing four essential transcription factors (Oct3/4, Sox2, c-Myc, and Klf4) into fibroblasts, Yamanaka and colleagues have reprogrammed the cells into pluripotent stem cells. Using this technique, they and others have shown that iPSCs can be differentiated into endothelial cells ([@B103]). Studies have shown that iPSC derived endothelial cells are capable of angiogenesis and reendothelialization to form vascular networks *in vitro* ([@B107]). Preclinical studies also showed the promising therapeutic potential of iPSCs ([@B31]). Although teratoma formation ([@B96]) and the potential of tumorigenicity of transplanted cells ([@B123]) are challenges in the clinical applications of iPSCs, iPSCs generated via non-genetic based techniques ([@B85]) will improve the safety to overcome those disadvantage. Because iPSCs can be derived from mature somatic cells, the cell source is easy to obtain. Furthermore, the source of iPSCs can be autologous, so there is no need for immunosuppression when delivery. These features make iPSCs an attractive cell source for regenerative medicine.

AFSCs
-----

Amniotic fluid derived stem cells (AFSCs) have been documented to be a special type of stem cells that possess a comprehensive multi-differentiation potential ([@B89]). Preclinical studies have shown that AFSCs can differentiate into vascular cell lineages to improve blood supply ([@B61]) or promote the regeneration of myocytes through their paracrine effects ([@B8]). Besides, AFSCs also possess several advantages which make them a potential therapeutic approach. First, ASFCs are easy to be obtained from amniocentesis specimens which are used for prenatal genetic diagnosis. Second, the obtained ASFCs, which are c-Kit positive, can be readily expanded *ex vivo* with a doubling time of 36 h. Third, ASFCs can be differentiated into cell types including adipogenic, osteogenic, myogenic, endothelial, neuronal, and hepatic lineages ([@B89]). More importantly, it has been recently reported that AFCSs can induce immunosuppressive activities of regulatory T cells (Tregs) to promote allograft survival in animal models of allogeneic transplantation ([@B89]). With more extensive studies being conducted, detailed molecular mechanisms have been proposed. A most recent study has demonstrated that several properties of AFSCs including immunoregulatory functions, cell differentiation toward multiple lineages, and migratory potency are regulated by sphingosine-1-phosphate (S1P) ([@B88]).

MNCs
----

Mononuclear cells, which can be isolated from BM and peripheral blood, are extensively studied in tissue engineering and regenerative medicine. They can be harvested from BM and peripheral blood by density gradient centrifugation with no need for *ex vivo* expansion. Moreover, MNCs are heterogenic which contain several types of stem/progenitor cells such as MSCs and EPCs. These cells are capable of differentiating into vascular and/or myocytes, or secrete growth factors improving the regeneration of injured tissues ([@B42]). These features allow quick autologous application after harvest, so MNCs are widely used as therapeutic cells in CVDs ([@B30]). However, recent systemic review and meta-analysis of the clinical efficacy of MNC transplantation only reveal modest clinical benefit. For PAD, improvements could be achieved in wound healing, amputation-free survival, pain-free walking, resting pain, and ulcer healing, but administration of MNCs could not improve the primary end-point of limb amputation compared with placebo ([@B86]; [@B83]). Another recent meta-analysis consisting of 2037 patients with acute MI has shown that MNC therapy only modestly improved left ventricular ejection fraction (LVEF) and infarct size ([@B16]). Despite the publication bias and possible lack of statistical power, several aspects during MNC administration could be improved to achieve better clinical results, for instance, refinement of cell delivery strategy to enhance cell survival and function. Recent progress made in the decelluarized scaffolds, which create the scaffolds enriched in structural extracellular matrix components that support cell attachment and infiltration *in vitro* and *in vivo* ([@B14]), stimulates great interest. Moreover, current genomic sequencing and proteomic techniques could also be utilized to identify essential pathways to improve the survival and function of transplanted cells.

CPCs
----

After the introduction of cardiac progenitor cells (CPCs), researchers began to determine the possibility of the experimental and clinical usage of CPCs as a potential therapeutic agent. CPCs are a group of heterogeneous cells residing in the cardiac tissue ([@B98]). After the identification of CPCs, researchers have discovered different cardiac resident cellular pools in human or murine heart, showing a variety of stem cell markers, including c-Kit^+^, stem cell antigen-1^+^ (Sca-1^+^), Islet 1^+^ (Isl-1^+^), stage-specific embryonic antigen-1^+^ (SSEA-11^+^), cardiospheres (CS), cardiospheres-derived (CD), and side population (SP), which has recently been reviewed extensively by [@B5], [@B6]). CPCs can self-renew, and they can also differentiate into three different cardiac cell types including cardiomyocytes, smooth muscle cells and endothelial cells ([@B105]; [@B6]). It has been reported that embryonic heart tubes derived CPCs can differentiate into pacemaker-like cells through endothelin-1 factor involved signaling ([@B128]). Recently, engineered cardiac pacemakers containing both CPC-derived pacemaker-like cells and EPCs have demonstrated the promising potential to ameliorate sinus node malfunction ([@B126]). Meanwhile, accumulating studies have shown that CPCs promote cardiac tissue restoration after CVD by releasing anti-apoptotic and angiogenic signals in a paracrine manner ([@B36]). It has been shown that CPC-derived exosomes promoted angiogenesis, cardiomyocyte survival and proliferation, and reduced cell apoptosis ([@B62]). Analysis of CPC-based clinical trials has revealed that patients suffering from heart-related diseases benefit from CPC-based therapy ([@B6]).

EPCs
----

[@B4] initially isolated angioblasts with endothelial lineage potential from human peripheral blood and named them "EPCs." They also found that these EPCs can differentiate into endothelial-like cells *in vitro* and participate in neovascularization in animal models of ischemia. Later, EPCs have been shown to migrate to peripheral blood from BM to participate in repairing dysfunctional endothelia and decreasing cardiovascular risk factor related endothelial injury by directly infusing into and forming new vessels or secreting pro-angiogenic growth factors or cytokines ([@B2]). Although an increasing number of reports have been documented to identify EPCs, there is still a lack of unambiguous and consistent definition of EPCs. Generally, EPCs are a group of cells which are characterized by positively expressing VEGFR2/Flk1, CD133/AC133, and CD34 at early stages; while at late stages when they gradually differentiate into endothelial cells, EPCs start to express endothelial markers including VE-cadherin, vWF, and endothelial nitric oxide synthase (eNOS) ([@B1]). Accumulating studies indicates that early EPCs promotes angiogenesis in a paracrine manner, and the late stage EPCs directly participate in endothelial neovascularization ([@B1]).

EPC Based Cell Therapy in CVDs
==============================

It is well-known that the integrity and functional activity of the endothelial monolayer are maintained by replication and migration of neighboring mature endothelial cells under physiological conditions. However, a series of clinical and pre-clinical studies have provided the evidence that in conditions of endothelial injury, regeneration of endothelial monolayer is assisted by EPCs homing to the artery wall. A critical early event in CVDs is endothelial dysfunction, which is perpetuated during the exposure of cardiovascular risk factors including hypercholesterolemia, metabolic syndrome, diabetes, hypertension, dyslipidemia, aging, and smoking. It has been reported that the number of circulating EPCs is inversely correlated with the presence of cardiovascular risk factors ([@B60]; [@B82]). Over the last two decades, extensive investigations in clinical and preclinical studies indicate that EPCs are a promising option to treat CVDs such as MI. The findings of EPC cell therapy for MI in animal studies have been summarized in **Table [1](#T1){ref-type="table"}**. Accumulating clinical trials have evaluated the safety and efficacy of EPCs for CVDs treatment, as summarized in **Table [2](#T2){ref-type="table"}**. As revealed in **Table [2](#T2){ref-type="table"}**, the clinical outcomes of the stem/progenitor cell-based therapy only achieved modest benefits, so more strategies should be employed to improve the stem/progenitor cell-based therapy.

###### 

Stem cell/EPC therapy in animal models of MI.

  Animal model   Transplanted cell type                                  Delivery strategy                                                                      Outcomes                                                                                                                                                                                    Reference
  -------------- ------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Mouse MI       Mouse BM-EPCs                                           Intravenous injection                                                                  EPC incorporated into neovascularization foci at infarct border                                                                                                                             [@B3]
  Mouse MI       Bone marrow derived mouse Lin- c-kit+                   Intramyocardial injection                                                              Newly formed myocardium occupied 68% of the infarcted portion of the ventricle were observed                                                                                                [@B72]
  Rat MI         Human peripheral blood EPCs                             Intravenous injection                                                                  EPCs incorporated into foci of neovascularization, smaller ventricular dimensions and ventricular scarring; increased fractional shortening, capillary density                              [@B45]
  Rat MI         Human peripheral blood CD34^+^ cells                    Tail vein injection                                                                    Decreased apoptosis of hypertrophied myocytes in the peri-infarct region, reduced collagen deposition, increased myocardium survival and cardiac function                                   [@B47]
  Pig MI         Pig MNCs                                                Trans-endocardial injection                                                            Increased systolic function, regional blood flow, collateral vessel formation, and decreased ischemic area                                                                                  [@B41]
  Pig MI         Pig MSCs                                                Intramyocardial injection                                                              Decreased degree of contractile dysfunction and wall thinning                                                                                                                               [@B99]
  Rat MI         Rat MSCs transduced Akt1                                Intramyocardial injection                                                              Inhibited the process of cardiac remodeling, restored myocardial volume                                                                                                                     [@B59]
  Rat MI         Human peripheral blood CD34^+^ angioblasts (EPCs)       Tail vein injection                                                                    Dose-dependent neovascularization with development of larger-sized capillaries; improve cardiac function through inhibiting apoptosis and promoting proliferation of cardiomyocytes         [@B95]
  Rat MI         Rat ASCs                                                Sheet technology (monolayered cell graft placed on the surface of the anterior scar)   ASCs reversed wall thinning in scar area and improve cardiac function. ASCs triggers angiogenesis and differentiate into vessels and cardiomyocytes                                         [@B67]
  Rat MI         Rat umbilical cord blood CD133^+^ cells                 Intravenous infusion                                                                   Scar thinning and LV systolic dilatation were prevented                                                                                                                                     [@B52]
  Pig MI         Pig CD34^+^                                             Intracoronary injection                                                                Improved cardiac repair and collateral vessel formation                                                                                                                                     [@B127]
  Rat MI         Human EPCs accompanied with SDF-1                       Intramyocardial injection                                                              Improved fractional shorting, left ventricular developing pressure, coronary flow rates, and neovascularization. Reduced the number of inflammatory cells and the rate of apoptotic cells   [@B94]
  Mouse MI       Human myoendothelial cells                              Intramyocardial injection                                                              Improved left ventricular function. Increased angiogenesis. Stimulated proliferation and survival cardiomyocytes. Reduced scar tissue                                                       [@B71]
  Rat MI         ECM scaffold supplemented with EPCs primed with SDF-1   Sutured to the anterolateral left ventricular wall                                     Increased VEGF level, vessel density, microvascular perfusion, vasculogenic response, and decreased scar formation                                                                          [@B25]
  Rat MI         Rat peripheral blood EPCs transduced with IGF-1         Intramyocardial injection                                                              Increased cardiac function, cardiomyocyte proliferation, and capillary density, decreased cardiac apoptosis                                                                                 [@B97]
  Pig MI         Human embryonic stem cells                              Fibrin-cell path applied to the LV anterior wall of the MI area                        Improved left ventricular function and neovascularization                                                                                                                                   [@B120]
                                                                                                                                                                                                                                                                                                                                                            

###### 

Stem/progenitor cell/EPC therapy in clinical studies of CVDs.

  Trial design                                                                                                        Disease                             Cell type                                                              Delivery strategy                           Outcomes                                                                                                                        Reference
  ------------------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -----------
  22 Bilateral ischemia patients, 25 unilateral ischemia patients, within-patient controls                            CLI                                 MNCs derived from BM or peripheral blood (PB)                          Intramuscular injection                     Improved transcutaneous oxygen pressure (TcPO2), rest pain, pain-free walking time, and ankle-brachial index (ABI)              [@B109]
  7 Patients, no controls                                                                                             CLI                                 BM derived MNCs                                                        Intramuscular injection                     Improved ABI, TcPO2, pain-free walking time, and leg blood flow                                                                 [@B34]
  6 Patients, no controls                                                                                             Acute myocardial infarction (AMI)   PB CD34^+^ cells                                                       Intracoronary injection                     Improved wall motion score index                                                                                                [@B7]
  44 Cell-injected patients, 22 control                                                                               AMI                                 BM-MNCs                                                                Intracoronary injection                     Increased LVEF and peak systolic velocities the infarcted wall longitudinal contraction                                         [@B65]
  41 Cell-injected patients, 45 control                                                                               ST-segment elevation MI             BM-MNCs                                                                Intracoronary injection                     Increased LVEF, no improvement of myocardial viability of infarcted area                                                        [@B11]
  7 Patients, non-randomized control                                                                                  Anterior MI                         PB CD34^+^ cells                                                       Transcoronary, intracoronary infusion       Decreased end-systolic volume                                                                                                   [@B18]
  7 Patients, no controls                                                                                             AMI                                 PB CD34^+^ cells                                                       Intracardiac infusion                       Increased LVEF, vascularization, and the regeneration of myocardial structure                                                   [@B74]
  28 Patients, no controls                                                                                            CLI                                 CD34^+^ CD133^+^ EPCs                                                  Intramuscular injection                     Improved limb salvage rate and attenuated pain scale                                                                            [@B49]
  25 Cell-injected patients, 25 placebo-injected patients; Randomized double-blinded trial                            Chronic myocardial ischemia         BM-MNCs                                                                Intramyocardial infusion                    Improved E/e' and E/A ratios, increased LVEF                                                                                    [@B111]
  112 Cell-injected patients, 56 placebo-injected patients; Phase II, prospective, double-blinded, randomized trial   Refractory angina                   CD34^+^ cells                                                          Intramyocardial infusion                    Improved exercise tolerance                                                                                                     [@B56]
  71 Cell-injected patients, 71 placebo-injected patients; Phase III, randomized, double-blinded trial                MI                                  CD133^+^ cells                                                         Intramyocardial infusion                    Patients received CD133^+^ cell injection had higher LVEF                                                                       [@B20]
  17 Patients, no control, Phase I/II clinical trial                                                                  CLI                                 Granulocyte-colony stimulating factor (GCSF) mobilized CD34^+^ cells   Intramuscular injection                     Improved toe brachial pressure index and TcPO2, pain scale, ulcer size, and exercise tolerance                                  [@B46]
  25 Patients, no control                                                                                             CLI                                 GCSF mobilized PB CD34^+^ cells                                        Intramuscular injection                     Improved pain-free walking time, ABI, TcPO2, and decreased pain score                                                           [@B19]
  11 Patients, no control; Phase II clinical trial                                                                    CLI                                 GCSF mobilized PB CD34^+^ cells                                        Intramuscular injection                     Increased pain scale, skin perfusion pressure, TcPO2, total walking distance, toe brachial pressure index, and CLI-free ratio   [@B28]
  49 Patients, no control                                                                                             CLI                                 BM-MNCs                                                                Intramuscular and intraarterial injection   Limb amputations were delayed; Improved ABI, rest pain, and ulcer healing                                                       [@B24]
                                                                                                                                                                                                                                                                                                                                                                                                             

EPC Based Therapy for Ischemic Vascular Diseases
================================================

The therapeutic efficacy of EPCs was not only documented in the studies of CVDs but also in the peripheral artery diseases (PAD). PAD is commonly referred to as the ischemia of limbs associated with atherosclerotic occlusion ([@B73]). Peripheral arteries supply oxygenated blood and nutrients to the legs and feet and narrowing of these arteries results in PAD. The most common symptom of PAD is the pain with walking which is also known as intermittent claudication ([@B73]). Critical limb ischemia (CLI) is the most severe clinical manifestation of PAD affecting a limb, if not interrupted, CLI could lead to ischemic ulcerations or even gangrene ([@B73]). In preclinical studies, the most adopted animal model is the hindlimb ischemia model (HLI) ([@B70]). In the HLI model, the femoral artery is ligated to reduce the blood supply to the lower leg which induces the angiogenesis to compensate for the reduced blood flow ([@B54]). The therapeutic efficacy of EPCs have been evaluated by this model by many groups, and **Table [3](#T3){ref-type="table"}** summarizes the preclinical animal studies of EPC cell therapy for PAD.

###### 

Stem cell/EPC therapy in animal studies of PAD.

  Animal model           Transplanted cell type                                 Delivery strategy                                   Outcomes                                                                                                                                                                        Reference
  ---------------------- ------------------------------------------------------ --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Mouse and rabbit HLI   Human CD34^+^; mouse Flk-1^+^                          Tail vein injection                                 EPC incorporated into sites of active angiogenesis                                                                                                                              [@B4]
  Mouse HLI              Human EPC                                              Intracardiac injection                              Ischemic hindlimb blood flow increased, capillary density increased, limb loss rate decreased                                                                                   [@B40]
  Rat HLI                Human CD34^+^ NMC (EPCs)                               Intramuscular injection                             Neovascularization and blood flow increased in ischemic hindlimb                                                                                                                [@B69]
  Mouse HLI              Human CD34^+^ cells                                    Intramuscular injection                             Blood flow restored in diabetic mice but not in non-diabetic mice                                                                                                               [@B93]
  Rabbit HLI             Rabbit BM-MNCs                                         Intramuscular injection                             More angiographically detectable collateral vessel, improved blood perfusion                                                                                                    [@B102]
  Mouse HLI              VEGF gene transduced Human EPCs                        Tail vein injection                                 Neovascularization and blood flow recovery improved, and limb necrosis was reduced                                                                                              [@B37]
  Mouse HLI              Human EPCs accompanied with SDF-1                      Intramuscular SDF-1 and intravenous EPC injection   Improved local accumulation of EPCs in ischemic muscle, ischemic tissue perfusion, and capillary density                                                                        [@B122]
  Mouse HLI              Human cord blood CD34^+^ KDR^+^ or CD34^+^ KDR-cells   Intramuscular injection                             CD34^+^ KDR^+^ cells significantly improved limb salvage and neovascularization, reduced endothelial cell apoptosis and interstitial fibrosis compared with CD34^+^ KDR-cells   [@B57]
  Mouse HLI              Human umbilical cord blood CD133^+^ EPCs               Tail vein injection                                 Increased neovascularization and improved ischemic limb salvage                                                                                                                 [@B124]
  Rat HLI                Human peripheral blood CD133^+^ progenitor cells       Intramuscular injection                             Increased arteriole and capillary density                                                                                                                                       [@B106]
  Mouse HLI              Human EPCs and smooth muscle progenitor cells          Intravenous injection                               Vessel density and foot perfusion increased                                                                                                                                     [@B23]
  Mouse HLI              Mouse MNCs                                             Intramuscular injection                             Increased blood flow ratio and capillary density; improved ankle-brachial index value, walking distance, pain scale, and TcPO2                                                  [@B125]
  Mouse HLI              Human iPSC-ECS                                         Intramuscular injection                             Increased capillary density and blood perfusion ratio                                                                                                                           [@B91]
  Mouse HLI              Human HUVECs and umbilical cord MSCs                   Intramuscular injection                             Blood perfusion recovered, increased vessel formation                                                                                                                           [@B12]
  Mouse HLI              Human MNCs, ESC, and iPSC                              Intramuscular injection                             Increased neovascularization and decreased hindlimb ischemia                                                                                                                    [@B48]
  Mouse HLI              Human AFSCs                                            Intramuscular injection                             Increased limb salvage, limb blood perfusion, and capillary and arteriole density                                                                                               [@B55]
                                                                                                                                                                                                                                                                                                                    

Approaches for Enhancing EPC Therapy in Diseases
================================================

Although EPCs possess exciting therapeutic potency, their limited plasticity and amount in patients with ischemic cardiac or ischemic vascular disease have become the obstacle to the success in EPC therapy. It has been reported that compromised EPC availability and repair potential to regenerate the injured endothelial monolayer mainly resulted from the influence of cardiovascular risk factors such as aging, smoking, diabetes, hypertension, and hypercholesterolemia ([@B78], [@B79]). As summarized, the clinical outcome of EPC based therapy was modest, and large-scale clinical trials have not been conducted. One of the reasons is that there is a lack of suitable transplantation models. Studies in animal models suggested that BM-MNCs or EPCs could home to ischemic tissues and restore the blood supply, however, during atherosclerosis acute surgical resection has little resemblance to chronic occlusion ([@B83]). Moreover, because of the heterogeneity between patients, in clinical trials, the selection of patient population for stem/progenitor cell-based therapy may not be optimized. These problems should be addressed before the clinical transfer of EPC based cell therapy. Therefore, an increasing number of studies have been focusing on the strategies to enhance the therapeutic efficacy of EPCs ([@B76]). Various modifiers including chemokine receptors, growth factors, signaling molecules or factors, medicines, and physical exercise have been demonstrated to enhance the therapeutic effects of EPCs.

The key factors shown to enhance the cell-based therapeutics in CVDs include but not limited to: chemokine receptors such as CXCR2 ([@B35]), CXCR4 ([@B39]), CX3CR1 ([@B33]), CXCR7 ([@B129]), and CCR5 ([@B130]); growth factors and their receptors such as VEGF1/2/3 ([@B101]; [@B104]), PDGF ([@B90]), FGF-1/2 ([@B90]; [@B13]), and so on. Signaling molecules and factors such as eNOS/nitric oxide ([@B44]; [@B15]), AMP-activated protein kinase (AMPK) ([@B113]), heme-oxygenase-1 (HO-1) ([@B92]), and manganese superoxide dismutase (MnSOD) ([@B63]), have also been shown to play important roles in EPC biology. Additionally, several transcription factors signaling including Homeobox A9 (HOXA9), Akt/Forkhead box-containing protein O subfamily (Akt-FOXO), and peroxisome proliferator-activated regulator-gamma (PPARγ) have been suggested to be involved in regulating the function of EPCs ([@B78]). Moreover, many medications used for prevention of CVDs have also been shown to increase the level of EPCs such as statins ([@B81]; [@B112]) and angiotensin II receptor antagonists ([@B75]), etc. [@B112] demonstrated that statins could improve the mobilization, derivation, and colonial growth of late outgrowth EPCs. They have also shown that pravastatin increased the capillary density in chronic myocardial ischemia by 46% in an animal model. More interestingly, it has been reported that exercise could improve the function of EPCs ([@B32]). The underlying mechanism between exercise and EPCs has mainly been linked to CXCR4 signaling, VEGF release, and nitric oxide (NO) bioavailability. VEGF has been shown to be important in angiogenesis. Studies have shown that after exercise training, the expression level of VEGF and its receptors in mice were significantly increased in post-MI. Meanwhile, the mice preconditioned with exercise expressed higher level of VEGF and its receptors compared with mice without exercise preconditioning ([@B118]). In an animal model of hypertension, exercise significantly increased EPC levels and also resulted in vascular repair in a VEGF/eNOS dependent manner ([@B22]). Studies also demonstrated that exercise training increased the expression level of CXCR4 and phosphorylation level of Janus kinase-2 (JAK-2) of EPCs, improved the endothelial function *in vitro* and reendothelialization capacity of EPCs *in vivo*([@B119]).

Studies have been performed to identify the key regulators to rescue the defective functions of EPCs from patients exposed to cardiovascular risk factors such as diabetes and aging. For instance, EPC transduced with Akt/HO-1 displayed increased MI recovery in nude mice ([@B9]). The importance of eNOS in EPC angiogenesis has also been evaluated by different groups. In a rat balloon injury model, the neointimal hyperplasia was inhibited, and vascular function was restored by transplanting eNOS overexpressed EPCs ([@B15]). Also, it has been shown that overexpressing eNOS in EPCs isolated from coronary artery disease displayed increased functions such as proliferation, differentiation, migration, and integration into tube-like structures *in vitro* ([@B44]). Accumulating studies have demonstrated the importance of chemokine receptors and their cognate ligands in EPC survival and function. CXCR4 has been shown to play a critical role in EPC mobilization and angiogenesis *in vivo* ([@B39]). Recently, we have shown that CXCR2 macromolecular signaling complex is essential in mediating EPC homing and angiogenesis *in vitro* and *in vivo* ([@B35]). Therefore, approaches such as genetic modification of EPCs to modify the expression of the chemokine receptors and growth factor receptors, or pretreatment of cells with chemokines or growth factors to improve the angiogenic signaling activities, rejuvenate the cells, or enhance the survival of EPCs could be investigated to address the limitations of EPC transplantation. Moreover, the findings of the positive effects of medications and physical exercise provide additional options to enhance the efficacy of EPC therapy in cost-efficient manner.

Conclusion
==========

Although clinical trials and preclinical studies have shown that EPCs and other stem cell and progenitor cells based therapy possess great therapeutic potential to improve cardiac function and blood perfusion in MI and PAD, obstacles still exist to be overcome before widespread application of EPCs in the treatment of CVD ([@B87]). Cell isolation, characterization, modification, and processing strategies must be further studied and refined to achieve enhanced therapeutic efficacy. For instance, there is still lack of consistent definition of EPCs, so further study is needed to standardize methods to define EPCs, through both lineage tracing and functional analysis ([@B64]). Meanwhile, upregulation of certain circulating progenitor cells such as circulating osteoprogenitor cells may result in vascular calcification which is a cardiovascular risk factor ([@B80]). Moreover, the cell infusion approach, dosing regimens, as well as the cell survival after delivery are also needed to be improved to achieve optimal outcomes ([@B26]). Due to the possibility of occurrence of teratoma formation and tumorigenesis, especially during the transplantation of iPSCs, the safety of the stem/progenitor cell-based therapies should also be monitored ([@B123]). In summary, previous clinical trials and preclinical studies have shed light on the EPC based therapy for treating CVDs. With more efforts to understand the biology of stem/progenitor cells and continued commitment to preclinical and clinical studies, stem/progenitor cell-based therapy may present an integral part of routine regenerative therapy for CVDs in the future.
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